^
    Back
    Association details:
    Biomarker:CCND1 amplification
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

    Excerpt:
    ...Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other functional alteration at the G1/S checkpoint....
    Trial ID:
    NCT01037790
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial

    Published date:
    11/17/2020
    Excerpt:
    307 patients were randomized to LET (n=103) or LET+PALBO (n=204) for 14 wks...Lower levels of ER, higher levels of cyclin-E1, and amplification of cyclin-D1 were each significantly associated with a greater chance of non-CCCA with LET+PALBO….These results suggest that multiple identifiable mechanisms of de novo resistance to PALBO are likely to exist in primary ER+ BC.
    Secondary therapy:
    letrozole
    Trial ID:
    PALLET